Scholarlink

Purpose <p>This systematic review and meta-analysis aimed to compare the clinical and angiographic outcomes of the LVIS versus the Enterprise stent for the treatment of intracranial aneurysms (IAs).</p> Methods <p>Eligible studies were extracted from PubMed, Scopus, and Embase comparing LVIS/Enterprise. Data on angiographic occlusion rates, neurological deficits, in-stent stenosis, hemorrhagic complications, thromboembolic complications and aneurysm recanalization were analyzed with statistical methods.</p> Results <p>5 observational studies (912 patients: 457 treated with LVIS and 455 with Enterprise) were analyzed. LVIS was linked to a significantly lower likelihood of Raymond-Roy Occlusion Classification (RROC) Class 3 (RR 0.30; 95% CI 0.13–0.71; I²=0%) and aneurysm recanalization (RR 0.38; 95% CI 0.18–0.82; I²=0%). No statistically significant differences were found between the two groups regarding mRS 0–2, RROC Class 1 or 2, or the incidence of neurological deficits, in-stent stenosis, hemorrhagic or thromboembolic events.</p> Conclusion <p>LVIS and Enterprise demonstrate safety and efficacy in the endovascular management of IAs. LVIS may provide improved angiographic outcomes by lowering the risk of recurrence and incomplete occlusion. These findings support its potential advantage in treating complex aneurysms. Further confirmation through randomized controlled trials (RCT) is needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LVIS versus enterprise stents for stent-assisted coiling of intracranial aneurysms: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年10月2日

查看全文
  • Lucca Tamara Alves Carretta,
  • Ocilio Ribeiro Gonçalves,
  • Mariana Lee Han,
  • Kenzo Ogasawara Donato,
  • Yasmin Picanço Silva,
  • Luciano Falcão,
  • Rian Barreto Arrais Rodrigues de Morais,
  • Nicole Baptista de Oliveira,
  • Mariana Letícia de Bastos Maximiano,
  • Ahmet Günkan

摘要

Purpose

This systematic review and meta-analysis aimed to compare the clinical and angiographic outcomes of the LVIS versus the Enterprise stent for the treatment of intracranial aneurysms (IAs).

Methods

Eligible studies were extracted from PubMed, Scopus, and Embase comparing LVIS/Enterprise. Data on angiographic occlusion rates, neurological deficits, in-stent stenosis, hemorrhagic complications, thromboembolic complications and aneurysm recanalization were analyzed with statistical methods.

Results

5 observational studies (912 patients: 457 treated with LVIS and 455 with Enterprise) were analyzed. LVIS was linked to a significantly lower likelihood of Raymond-Roy Occlusion Classification (RROC) Class 3 (RR 0.30; 95% CI 0.13–0.71; I²=0%) and aneurysm recanalization (RR 0.38; 95% CI 0.18–0.82; I²=0%). No statistically significant differences were found between the two groups regarding mRS 0–2, RROC Class 1 or 2, or the incidence of neurological deficits, in-stent stenosis, hemorrhagic or thromboembolic events.

Conclusion

LVIS and Enterprise demonstrate safety and efficacy in the endovascular management of IAs. LVIS may provide improved angiographic outcomes by lowering the risk of recurrence and incomplete occlusion. These findings support its potential advantage in treating complex aneurysms. Further confirmation through randomized controlled trials (RCT) is needed.